Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Entecavir

FDA-approved product (tablet, oral), marketed as Baraclude, Entecavir.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Entecavir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis B virus infection
  • Hepatitis B virus infection
  • Liver disease
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
FDA pharmacologic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF10; FDA class Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Entecavir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Entecavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background

    NCT02053727 · start 2014-07

    Registered record
    Registry ID
    NCT02053727
    Conditions
    Rheumatoid Arthritis; Chronic Hepatitis B
    Interventions
    Abatacept; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2014-07
    Completion
    2018-06-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis; Chronic Hepatitis B
    InterventionAbatacept; Placebo
    PhaseNot applicable
    Registry statusWithdrawn

  • A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase

    NCT02263079 · start 2014-06-16

    Registered record
    Registry ID
    NCT02263079
    Conditions
    Pediatric Immuno-Tolerant Chronic Hepatitis B
    Interventions
    Entecavir; Lamivudine; Pegylated Interferon Alfa-2A
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-06-16
    Completion
    2020-01-29
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatric Immuno-Tolerant Chronic Hepatitis B
    InterventionEntecavir; Lamivudine; Pegylated Interferon Alfa-2A
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B

    NCT01943799 · start 2013-09-13

    Registered record
    Registry ID
    NCT01943799
    Conditions
    Chronic HBV Infection
    Interventions
    GS-4774; OAV Regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-09-13
    Completion
    2015-03-03
    Enrolment
    178

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic HBV Infection
    InterventionGS-4774; OAV Regimen
    PhasePhase 2
    Registry statusCompleted

  • Entecavir for Biological Agents Associated HBV Reactivation in Inflammatory Arthritis Patients

    NCT01907230 · start 2013-09-10

    Registered record
    Registry ID
    NCT01907230
    Conditions
    Rheumatoid Arthritis; Hepatitis B Reactivation; Exposure to Hepatitis B Virus
    Interventions
    Entecavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-09-10
    Completion
    2019-12-31
    Enrolment
    115

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis; Hepatitis B Reactivation; Exposure to Hepatitis B Virus
    InterventionEntecavir
    PhasePhase 4
    Registry statusUnknown

  • A Randomized Controlled Trial on the Efficacy of Tenofovir Disoproxil Fumarate (TDF)-Switch Therapy in Chronic Hepatitis B Patients With Incomplete Response to Entecavir

    NCT01918631 · start 2013-08

    Registered record
    Registry ID
    NCT01918631
    Conditions
    Chronic Heptitis B
    Interventions
    tenofovir disoproxil fumarate; Entecavir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-08
    Completion
    2017-01-31
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Heptitis B
    Interventiontenofovir disoproxil fumarate; Entecavir
    PhaseNot applicable
    Registry statusCompleted

  • Optimized Treatment and Regression of HBV-induced Early Cirrhosis

    NCT01938820 · start 2013-06

    Registered record
    Registry ID
    NCT01938820
    Conditions
    Liver Cirrhosis
    Interventions
    entecavir; Thymosin-α
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-06
    Completion
    2016-12
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhosis
    Interventionentecavir; Thymosin-α
    PhasePhase 4
    Registry statusCompleted

  • Comparison of the Efficacy of Entecavir and Tenofovir Monotherapy for the Treatment of Nucleos(t)Ide-naïve Patients With Chronic Hepatitis B in Korea

    NCT01776814 · start 2013-02

    Registered record
    Registry ID
    NCT01776814
    Conditions
    Chronic Hepatitis B
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2013-02
    Completion
    Not recorded
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B

    NCT02881008 · start 2012-11-14

    Registered record
    Registry ID
    NCT02881008
    Conditions
    Chronic Hepatitis B
    Interventions
    Entecavir; Myrcludex B
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2012-11-14
    Completion
    2014-10-04
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionEntecavir; Myrcludex B
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Tenofovir vs. Tenofovir Plus Entecavir in Entecavir-Resistant Chronic Hepatitis B

    NCT01639092 · start 2012-09-28

    Registered record
    Registry ID
    NCT01639092
    Conditions
    Chronic Viral Hepatitis B Without Delta-agent
    Interventions
    Tenofovir; Tenofovir; Entecavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-09-28
    Completion
    2018-03-29
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Viral Hepatitis B Without Delta-agent
    InterventionTenofovir; Tenofovir; Entecavir
    PhasePhase 4
    Registry statusCompleted

  • HBsAg Related Response Guided Therapy

    NCT01456312 · start 2012-09

    Registered record
    Registry ID
    NCT01456312
    Conditions
    Hepatitis B, Chronic
    Interventions
    Peginterferon alfa-2a; Entecavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2012-09
    Completion
    2016-08
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B, Chronic
    InterventionPeginterferon alfa-2a; Entecavir
    PhasePhase 4
    Registry statusUnknown

  • Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B

    NCT01595685 · start 2012-05

    Registered record
    Registry ID
    NCT01595685
    Conditions
    Chronic Viral Hepatitis B Without Delta-agent
    Interventions
    Telbivudine; Entecavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-05
    Completion
    2014-12
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Viral Hepatitis B Without Delta-agent
    InterventionTelbivudine; Entecavir
    PhasePhase 3
    Registry statusCompleted

  • Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue

    NCT01480284 · start 2011-11

    Registered record
    Registry ID
    NCT01480284
    Conditions
    Hepatitis B, Chronic
    Interventions
    GSK548470 300 mg tablet; ETV 0.5 mg capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-11
    Completion
    2014-11
    Enrolment
    166

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B, Chronic
    InterventionGSK548470 300 mg tablet; ETV 0.5 mg capsule
    PhasePhase 3
    Registry statusCompleted

  • Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation in Chronic Hepatitis B Patients

    NCT01641536 · start 2011-11

    Registered record
    Registry ID
    NCT01641536
    Conditions
    Hepatitis B, Chronic
    Interventions
    HB-110
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-11
    Completion
    2013-04
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B, Chronic
    InterventionHB-110
    PhasePhase 1
    Registry statusCompleted

  • Entecavir for Chronic Hepatitis B

    NCT01323452 · start 2010-11

    Registered record
    Registry ID
    NCT01323452
    Conditions
    Entecavir for Chronic Hepatitis B Patients
    Interventions
    Entecavir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-11
    Completion
    2011-03
    Enrolment
    418

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEntecavir for Chronic Hepatitis B Patients
    InterventionEntecavir
    PhaseNot recorded
    Registry statusCompleted

  • Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients

    NCT01027065 · start 2009-12

    Registered record
    Registry ID
    NCT01027065
    Conditions
    Chronic Hepatitis B
    Interventions
    CYT107+GenHevac+entecavir or tenofovir; CYT107+ entecavir or tenofovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2009-12
    Completion
    2013-03
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis B
    InterventionCYT107+GenHevac+entecavir or tenofovir; CYT107+ entecavir or tenofovir
    PhasePhase 1 / Phase 2
    Registry statusUnknown